(Q36057039)

English

Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health an

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

1 reference

Europe PubMed Central

Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health an (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

0 references

1 reference

based on heuristic

inferred from title

cost-effectiveness analysis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

author name string

Uwe Siebert

1

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

Gaby Sroczynski

2

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

German Hepatitis C Model GEHMO Group

3

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

HTA Expert Panel on Hepatitis C

4

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

publication date

1 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

International Journal of Technology Assessment in Health Care

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

55-65

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. Ribavirin-Interferon in Chronic Hepatitis Italian Group Investigators.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Making cost assessments based on RCTs more useful to decision-makers

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Myocardial revascularization for chronic stable angina. Analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Non-A, non-B post-transfusion hepatitis. Looking back in the second decade

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Tolerance and latent cellular rejection in long-term liver transplant recipients

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV).

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

High-priced technology can be good value for money.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Cost effectiveness of combination therapy for hepatitis C: a decision analytic model

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Estimating progression to cirrhosis in chronic hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Issues in the cross-national assessment of health technology

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Is severe liver disease a common outcome for people with chronic hepatitis C?

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Customising an international disease management model to the needs of individual countries. Application to upper gastrointestinal disease

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

21 January 2018

Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimating country-specific cost-effectiveness from multinational clinical trials

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050075

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1017/S0266462305050075

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36057039&oldid=1629112360"